New personalized vaccine takes on tough cancers
NCT ID NCT07587827
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system. The main goals are to find a safe dose and see if the vaccine can help slow the cancer's growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized cancer vaccine (DNA neoantigen vaccine + MVA viral vector + ipilimumab)
What this could lead to
If it works, this could point toward a new treatment option for advanced colon and pancreatic cancers that are hard to treat.
What could go wrong
This is a very early Phase 1 trial with only 77 people. It is designed mainly to check safety and find the right dose, not to prove it works. The vaccine is personalized, so it may not work for everyone, and side effects from the immune-boosting drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU Jean Minjoz
Besançon, 25000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges-François Leclerc
Dijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••